Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.
Top 5 Stories :
Pharm Exec's Emerging Pharma Leaders 2015 – Nominate Now Pharm Exec is looking for the fresh faces of pharma leadership. And we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more
Beyond the Blame Game: How Pharma is Learning to Collaborate Under the Affordable Care Act, the US made great strides in extending health coverage to millions of people who previously had none. Nevertheless, for many people who struggle with chronic illnesses, paying for medical care is a challenge. Read more
Sponsored
learn more about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study.
Read more
Marketing: Medical Devices vs. Pharma
If you've spent any time working in the device industry, you've probably heard pharma marketers make premature assumptions about what it takes to market a medical device. Read more
Deep Breadth: GSK Doubles Down on COPD and Asthma
It took FDA eight years to develop a blueprint for how generics manufacturers might establish an acceptable bioequivalence for Advair, GSK's blockbuster fluticasone propionate/salmeterol xinafoate combo inhaler. Read more
Trending on Social Media :
Pharma's Love Affair with Buzzwords
One unusual fact that I've learned from working in the life sciences sector for the greater part of this past decade is that we on the commercial side of the business have an unhealthy obsession with “buzzwords.” Read more
Income and Depression: A Predictive Model for Clinical Trials Patient Dropout
Limited research has been conducted on factors that impact patient dropout; some research suggests that patients who are less physically active were 7.3 times more likely to drop out of a clinical trial, whereas unemployed patients were 4.7 times more likely to drop out. Read more
A Blueprint for Launch
As new drug launches proliferate in the hotly contested specialty therapeutic space, companies are finding that success is often pre-determined by actions that take place very early in the development and commercialization cycle. Read more